Orchestra BioMed Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $360.54M
- P/E (TTM)
- –
- Dividend yield
- –
About Orchestra BioMed
Surgical & Medical Instruments & Apparatus, SIC 3841
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic medical technologies through risk-and-reward sharing partnerships with major global medical device companies. The company operates across two principal product development platforms: bioelectronic therapies and interventional devices. Its flagship bioelectronic candidate, Atrioventricular Interval Modulation (AVIM) Therapy, is an algorithmic, firmware-integrated treatment for uncontrolled hypertension in cardiac pacemaker patients, being co-developed under an exclusive global license and collaboration with Medtronic. Its lead interventional candidate, the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), is a drug-device combination delivering an extended-release sirolimus formulation for treating atherosclerotic artery disease, specifically targeting coronary in-stent restenosis and related vascular conditions.
The company's clinical research activities span multiple worldwide regions, including a global pivotal trial conducted across up to 130 sites globally for AVIM Therapy and a United States pivotal trial enrolling patients across up to 75 domestic sites for Virtue SAB. Orchestra BioMed operates primarily through collaboration frameworks with multinational device distributors and partners. The company's headquarters are not stated in the provided text.
Summary of the business section of Orchestra BioMed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Orchestra BioMed Holdings, Inc.
- Founded
- 2018
- Headquarters
- New Hope, PA
- Address
- 150 Union Square Drive 18938
- Phone
- (646) 343-9298
- Employees
- 86, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- OBIO
- Exchange
- Nasdaq
- IPO date
- Aug 5, 2020
- Shares outstanding
- 60M, Aug 6, 2026
- Public float
- $63.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-1.33 reverse, Nov 12, 2021
- SEC CIK
- 1814114
- CUSIP
- 68572M106
- ISIN
- US68572M1062
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David P. Hochman | See Remarks, Director | 1,509,519 |
| Darren Sherman | See Remarks, Director | 1,136,402 |
| Andrew Lawrence Taylor | Chief Financial Officer | 589,989 |
| Joshua Aiello | Principal Accounting Officer | 18,441 |
| Chris Cleary | Director | 29,153 |
| John Prosper Mack | Director | 66,544 |
| David Pacitti | Director | 54,750 |
| Eric S. Fain | Director | 107,130 |
| Jason Aryeh | Director | 118,118 |
| Pamela Ann Connealy | Director | 66,038 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 86 employees engaged in finance, clinical, research and development, engineering, regulatory and administration functions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 31, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 31, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 26, 2023 | Name change | Name changed from Health Sciences Acquisitions Corp 2 to Orchestra BioMed Holdings, Inc. |
| Jan 24, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 8, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 5, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 3, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |